Abstract
The aim of the preset study is to explain the role of irisin hormone levels in type-2 obese diabetic women and compare these levels with those in obese nondiabetic women. In addition, we investigated the relation of irisin levels with those of glycated hemoglobin (HbA1c) and body mass index (BMI) in the patients.
 Eighty eight subjects were included in this study, including 44 type-2 Iraqi obese diabetic women as a patients group, and 44 obese nondiabetic women as a control group. Serum irisin was measured by Enzyme-linked Immune-Sorbent assay (ELISA), while determination of glycosylated Hemoglobin was carried out by The SD A1c CareTM system. Diabetic type-2 obese women showed a highly significant decrease in the levels of serum irisin when compared to levels in obese non-diabetic women, while no significant changes were observed in the mean±SD values when comparing age and duration of DM. In the patients, a negative correlation was found between serum irisin and HbA1c while no significant correlation was recorded between the hormone levels and BMI.
Highlights
Type-2 diabetic mellitus (T2DM) is typically a progressive metabolic disease caused by both environmental and genetic factors
The results revealed that no significant change was detected in the mean±SD levels of serum irisin when compared according to the age groups and duration of diabetes
Irisin, a circulating hormone-like myokine, is known to regulate energy homeostasis and mediate the health benefits of physical-exercise [13]
Summary
Type-2 diabetic mellitus (T2DM) is typically a progressive metabolic disease caused by both environmental and genetic factors. The pathogenesis of T2DM includes functional defects in all main organs governing metabolic control, involving liver, pancreatic beta-cells (β-cells), adipose tissue, and skeletal muscles These defects cause an impairment in the capacity of insulin for regulating wholebody glucose homeostasis; a condition generally referred to as “insulin resistance” (IR) [1]. Mean± SD values of age and duration of diabetes (years) of study subjects are presented in Table-1. The results in Table-1 show that the age range of all subjects is classified as: 55 years (25%) for type 2 obese diabetic women. While the age ranges of obese non-diabetic controls were 15.9%, 36.4%, 18.2%, 15.9%, and 13.6%, respectively It can be noticed from Table-1 that the mean duration of disease was 6.6±4.6 years. The duration of disease in obese diabetic women was less than 5 years in 40.9 %, 5-9 years in 29.5 %, and years and more in 29.5 %
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
